vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Strategy Inc (MSTR). Click either name above to swap in a different company.

Strategy Inc is the larger business by last-quarter revenue ($123.0M vs $77.6M, roughly 1.6× Bioceres Crop Solutions Corp.). On growth, Strategy Inc posted the faster year-over-year revenue change (1.9% vs -16.8%). Over the past eight quarters, Strategy Inc's revenue compounded faster (3.3% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Strategy Inc., formerly known as MicroStrategy, is an American company that provides business intelligence (BI) and mobile software. Founded in 1989 by Michael J. Saylor, Sanju Bansal, and Thomas Spahr, the firm develops software to analyze internal and external data in order to make business decisions and to develop mobile apps. It is a public company headquartered in Tysons Corner, Virginia, in the Washington metropolitan area. Its primary business analytics competitors include SAP SE Busin...

BIOX vs MSTR — Head-to-Head

Bigger by revenue
MSTR
MSTR
1.6× larger
MSTR
$123.0M
$77.6M
BIOX
Growing faster (revenue YoY)
MSTR
MSTR
+18.7% gap
MSTR
1.9%
-16.8%
BIOX
Faster 2-yr revenue CAGR
MSTR
MSTR
Annualised
MSTR
3.3%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
BIOX
BIOX
MSTR
MSTR
Revenue
$77.6M
$123.0M
Net Profit
$-7.4M
Gross Margin
46.8%
66.1%
Operating Margin
9.3%
Net Margin
-9.6%
Revenue YoY
-16.8%
1.9%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
MSTR
MSTR
Q4 25
$123.0M
Q3 25
$77.6M
$128.7M
Q2 25
$114.5M
Q1 25
$60.6M
$111.1M
Q4 24
$98.8M
$120.7M
Q3 24
$93.3M
$116.1M
Q2 24
$111.4M
Q1 24
$84.0M
$115.2M
Net Profit
BIOX
BIOX
MSTR
MSTR
Q4 25
Q3 25
$-7.4M
$2.8B
Q2 25
$10.0B
Q1 25
$-1.6M
$-4.2B
Q4 24
$605.2K
$-670.8M
Q3 24
$-6.2M
$-340.2M
Q2 24
$-102.6M
Q1 24
$9.8M
$-53.1M
Gross Margin
BIOX
BIOX
MSTR
MSTR
Q4 25
66.1%
Q3 25
46.8%
70.5%
Q2 25
68.8%
Q1 25
39.4%
69.4%
Q4 24
42.0%
71.7%
Q3 24
40.2%
70.4%
Q2 24
72.2%
Q1 24
50.8%
74.0%
Operating Margin
BIOX
BIOX
MSTR
MSTR
Q4 25
Q3 25
9.3%
Q2 25
Q1 25
1.5%
-5331.4%
Q4 24
14.5%
-842.1%
Q3 24
2.5%
-372.7%
Q2 24
-179.7%
Q1 24
15.7%
-176.8%
Net Margin
BIOX
BIOX
MSTR
MSTR
Q4 25
Q3 25
-9.6%
2164.1%
Q2 25
8752.7%
Q1 25
-2.6%
-3797.2%
Q4 24
0.6%
-555.8%
Q3 24
-6.6%
-293.1%
Q2 24
-92.0%
Q1 24
11.6%
-46.1%
EPS (diluted)
BIOX
BIOX
MSTR
MSTR
Q4 25
Q3 25
$-0.12
$8.42
Q2 25
$32.60
Q1 25
$-0.02
$-16.49
Q4 24
$0.00
$4.49
Q3 24
$-0.10
$-1.72
Q2 24
$-0.57
Q1 24
$0.14
$-0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
MSTR
MSTR
Cash + ST InvestmentsLiquidity on hand
$15.5M
$2.3B
Total DebtLower is stronger
$8.2B
Stockholders' EquityBook value
$288.3M
$44.1B
Total Assets
$734.9M
$61.6B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
MSTR
MSTR
Q4 25
$2.3B
Q3 25
$15.5M
$54.3M
Q2 25
$50.1M
Q1 25
$38.5M
$60.3M
Q4 24
$29.2M
$38.1M
Q3 24
$32.3M
$46.3M
Q2 24
$66.9M
Q1 24
$16.4M
$81.3M
Total Debt
BIOX
BIOX
MSTR
MSTR
Q4 25
$8.2B
Q3 25
$8.2B
Q2 25
$8.2B
Q1 25
$8.1B
Q4 24
$7.2B
Q3 24
$4.2B
Q2 24
$3.8B
Q1 24
$3.6B
Stockholders' Equity
BIOX
BIOX
MSTR
MSTR
Q4 25
$44.1B
Q3 25
$288.3M
$52.3B
Q2 25
$47.5B
Q1 25
$345.0M
$32.2B
Q4 24
$346.3M
$18.2B
Q3 24
$346.0M
$3.8B
Q2 24
$2.8B
Q1 24
$348.5M
$2.4B
Total Assets
BIOX
BIOX
MSTR
MSTR
Q4 25
$61.6B
Q3 25
$734.9M
$73.6B
Q2 25
$64.8B
Q1 25
$798.2M
$43.9B
Q4 24
$835.2M
$25.8B
Q3 24
$827.3M
$8.3B
Q2 24
$7.1B
Q1 24
$836.1M
$6.4B
Debt / Equity
BIOX
BIOX
MSTR
MSTR
Q4 25
0.19×
Q3 25
0.16×
Q2 25
0.17×
Q1 25
0.25×
Q4 24
0.39×
Q3 24
1.12×
Q2 24
1.36×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
MSTR
MSTR
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
MSTR
MSTR
Q4 25
Q3 25
$14.4M
$-8.3M
Q2 25
$-34.9M
Q1 25
$23.3M
$-2.4M
Q4 24
$-5.4M
$-17.3M
Q3 24
$5.2M
$-41.0M
Q2 24
$-23.3M
Q1 24
$-17.4M
$28.6M
Free Cash Flow
BIOX
BIOX
MSTR
MSTR
Q4 25
Q3 25
$-11.1M
Q2 25
$-37.0M
Q1 25
$-5.1M
Q4 24
$-17.6M
Q3 24
$-41.4M
Q2 24
$-24.1M
Q1 24
$27.0M
FCF Margin
BIOX
BIOX
MSTR
MSTR
Q4 25
Q3 25
-8.6%
Q2 25
-32.3%
Q1 25
-4.6%
Q4 24
-14.6%
Q3 24
-35.7%
Q2 24
-21.6%
Q1 24
23.5%
Capex Intensity
BIOX
BIOX
MSTR
MSTR
Q4 25
Q3 25
2.2%
Q2 25
1.8%
Q1 25
2.5%
Q4 24
0.2%
Q3 24
0.4%
Q2 24
0.6%
Q1 24
1.3%
Cash Conversion
BIOX
BIOX
MSTR
MSTR
Q4 25
Q3 25
-0.00×
Q2 25
-0.00×
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons